骨髓增生异常综合征患者血清乳酸脱氢酶检测的临床意义  

The clinical value of LDH measurement in patients with myeloid dysplastic syndromes

作　　者：夏海龙[1] 蒋玲[2] 夏瑞祥[1] 任立奋[1] 蔡学杰[1] 

机构地区：[1]安徽医科大学附属医院血液科,合肥230022 [2]淮南望峰岗机械厂医院

出　　处：《安徽医学》2002年第2期11-12,共2页Anhui Medical Journal

摘　　要：目的　检测骨髓增生异常综合征 (MDS)患者、再障患者及正常人血清乳酸脱氢酶 ,并研究其对MDS预后判定、诊断及与再障鉴别的临床意义。方法　采用国际血液学标准化委员会介绍的酶法。结果　MDS组与正常人组、再障组相比较血清LDH水平明显增高 ;再障组与正常人组相比较血清LDH水平无明显差异 ;MDS组中LDH明显增高组与LDH增高组相比较 ,LDH明显增高组中位生存期明显短于后者。结论　血清LDH水平可作为MDS与再障鉴别诊断、MDS预后不良的指标。Objective To assess the clinical significance of the level of LDH in MDS.Methods Using the enzyme method introduced by ICSH,to measure the level LDH in serum in 56 patients with myeloid dysplastic syndromes,18 patients with aplastic anemia and 20 normal persons,evaluate the value of level of LDH in the MDS diagnosis,prognosis and differentiatial diagnosis in aplastic anemia. Results (1) The level of LDH in MDS increased obviously compared with those in aplastic anemia patients (P<0.05),and in normal persons (P<0.05),(2)The survival period of the group with obviously increased LDH in MDS is much shorter than that with slightly increased LDH.Conclusion LDH measurement has more important value for the MDS differentiatial diagosis and evaluation of prognosis.

关 键 词：乳酸脱氢酶 骨髓增生异常综合征 再生障碍性贫血 

分 类 号：R446.11[医药卫生—诊断学]